SCHEMBL4409356

SCHEMBL4409356

CCOc1cc(OC)c(F)c(C(=O)C(=O)O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
TSHR P16473 2/20 0.40
HIF1A Q16665 1/20 0.40
KAT6A Q92794 1/20 0.39
ALDH1A1 P00352 1/20 0.38
RCE1 Q9Y256 1/20 0.38
MAPT P10636 3/20 0.38
ALOX15 P16050 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
AHR P35869 1/20 0.38
MAPK1 P28482 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
TP53 P04637 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
CYP1A1 P04798 1/20 0.36
CYP1B1 Q16678 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4395658 0.91 KDM4E (0.49) KDM4ETSHRKAT6ASMN1; SMN2TP53
SCHEMBL4403271 0.88 KDM4E (0.43) KDM4ETSHRMAPTNPC1RAB9A
SCHEMBL4410409 0.88 TSHR (0.45) KDM4ETSHRHIF1AKAT6AALDH1A1
SCHEMBL4409280 0.86 SMN1; SMN2 (0.41) KDM4EALDH1A1MAPTNPC1RAB9A
SCHEMBL4405792 0.82 KAT6A (0.43) KDM4EKAT6AALDH1A1MAPTALOX15
SCHEMBL4395957 0.78 TSHR (0.50) KDM4ETSHRKAT6AALDH1A1RCE1
SCHEMBL4404615 0.77 HSD17B10 (0.51) KDM4ETSHRHIF1AALDH1A1RCE1
SCHEMBL4406522 0.76 MAPT (0.42) KDM4EKAT6AMAPTNPC1RAB9A
SCHEMBL4398646 0.76 TSHR (0.45) TSHRMAPTNPC1RAB9AMEN1
SCHEMBL4406552 0.76 TSHR (0.41) KDM4ETSHRALDH1A1TP53MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 KDM4E 954/4885TSHR 3028/4885HIF1A 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.